Pharmaceutical company Incannex Healthcare Ltd (ASX: IHL) reports that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.
Incannex is developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and is an operator of psychedelic-assisted psychotherapy clinics.
Clarion Clinics Group Pty Ltd is a collaborative venture between IHL and three leading Australian psychedelics experts, Dr. Paul Liknaitzky, Professor Suresh Sundram and Sean O’Carroll, who are co-founders, key executives and directors of the company. Clarion’s first clinic will open its doors to patients in Q3 2023 and the company intends to expand rapidly following the successful operation of the first clinic.
The three world leading clinical psychedelic experts joining the Advisory Board are:
Dr Bill Richards, the Director of Therapy at Sunstone Therapies, and a psychologist in the Centre for Psychedelic and Consciousness Research at the Johns Hopkins School of Medicine, a consultant/trainer within numerous psychedelic research sites internationally, a teacher in the Program of Psychedelic Therapy and Research at the California Institute of Integral Studies, and also a clinician in private practice in Baltimore.
Dr Andrea Jungaberle serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation. She is a clinical specialist in anaesthesia and emergency medicine, a psychedelic therapist, and currently completing a certification in cognitive behavioural psychotherapy.
Professor Matthew Johnson is Professor of Psychiatry and Behavioural Sciences at Johns Hopkins. He is one of the world’s most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioural economics of drug use, addiction, and risk behaviour.
I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team,” Peter Widdows, Incannex Director, said.
“It’s a testament to the vision that Paul, Suresh and Sean are bringing together to provide this vital service to many people in great need. As Australia is the first country to legalise the use of psychedelic drugs in the treatment of mental illness, the eyes of the world are upon us, and having people of this calibre and experience on board will help us ensure we provide world-leading effective treatments in an ethical and safe way.”
